Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 25, 2009

View Archived Issues

Inhibitors of epithelial cancer stem cells identified with innovative screen

Snapshots of studies of CXA-101 alone and in combination with tazobactam presented at ICAAC: II

Discouraging results reported for bone agent ronacaleret

IPA-3 covalently binds to the regulatory domain of PAK1; new approach for kinase inhibition revealed

Bazedoxifene acetate is safe, tolerated and cost-effective in osteoporotic postmenopausal women

Toremifene prevents bone loss and increases bone mass density in androgen-deprived males

Adenovirus-based gene therapy restores trichromatic vision in adult color-blind primates

Novel IGF-I receptor antagonists identified by US scientists for the treatment of cancer

Roche claims alpha1A-adrenoceptor partial agonists for the treatment of urinary incontinence

Naphthoquinone derivatives for the treatment of leishmaniasis described by German scientists

Abbott describes positive allosteric modulators of alpha7 nicotinic receptor as analgesics

Adolor acquires rights to OpRA III from Lilly

AstraZeneca and Nektar Therapeutics sign agreement for drug development programs

Cell Therapeutics will focus resources on the approval of Opaxio for ovarian cancer

Neuralstem cleared to commence stem cell trial in amyotrophic lateral sclerosis

Sabril launched in U.S. for patients with difficult-to-treat epilepsy

Takeda San Francisco enters into sponsored research agreement with UCSF

Valeant advances retigabine program

Viralytics completes phase I melanoma trial and prepares for phase II

Abbott receives FDA approval for HIV-1/HIV-2 blood screening test

Genomica launches diagnostic kit for H1N1

Celera and Medco evaluate effect of KIF6 testing on statin therapy compliance

Kevetrin delays tumor growth in animal models of drug-resistant breast cancer

Lux Biosciences reports phase I safety and efficacy results for LX-214

Janssen-Cilag's Stelara approved in UK for plaque psoriasis

Modest positive results reported from phase III clinical trial in Thailand of HIV vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...